Skip to content
DataLookout
Start free
Menu

NCT04590664

Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

StatusTerminated
PhasePhase 1/2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 7 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Trial terminated Sponsor's reason: PI Decision Show 8 more changesShow less
    • Primary endpoint(s) modified
    • Results posted: Oct 28, 2026
    • Final enrollment: 9 participants (planned 24)
    • Primary completion date changed from estimate of Aug 15, 2025 to Feb 13, 2025
    • Eligibility criteria expanded, about 23 words
    • Secondary endpoints shortened, about 21 words
    • Study description revised
    • Site details revised
  2. Site contact updatedv7
  3. Primary completion date: Aug 15, 2024 to Aug 15, 2025v6
  4. Primary completion date: Aug 15, 2023 to Aug 15, 2024
    • Study completion date: Aug 15, 2023 to Aug 15, 2025
    v5
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 29, 2021 to Jan 15, 2021
    • Site details revised
    v3
  6. Start date: Oct 30, 2020 to Jan 29, 2021v2
  7. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of Adverse Events (Phase I)
Timeframe: Safety follow-up is 30 days after the last drug administered (at Day 36 +/- 1 day) *see protocol[

Arms and interventions

Treatment (verteporfin)Experimental

Patients receive verteporfin IV over 83 minutes weekly for 6 weeks in cycle 1, then weekly for 5 weeks in subsequent cycles. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.

Drugs: Verteporfin

Sites

1 site in 1 country

  • Emory University Hospital/Winship Cancer InstituteAtlanta, Georgia, United States